Low Risk of Central Nervous System Relapse Among Patients With T‐Cell/Histiocyte‐Rich Large B‐Cell Lymphoma Despite High‐Risk Disease Presentation
European Journal of Haematology · 2026-08 · 117 (2) · 358-365
DOI: 10.1111/ejh.70190 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 13.04.2026. Verfasst von Atte Karhu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Oulu, Oulu, Finland. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Lymphoma, Large B-Cell, Diffuse, Histiocytes, T-Lymphocytes. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Incyte.
Abstract (Originalsprache)
T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL) is a rare subtype of large B‐cell lymphoma (LBCL) for which central nervous system (CNS) relapse remains a devastating complication. The CNS International Prognostic Index (IPI) is usually used to predict the risk of CNS relapse. However, the overall risk of CNS relapse among patients with THRLBCL remains poorly known. To clarify the risk of CNS relapse in THRLBCL, data for 106 patients with THRLBCL diagnosed between 2000 and 2020 were collected from seven hospitals throughout Finland. The control data consisted of 660 patients with diffuse LBCL (DLBCL) diagnosed and treated in Oulu University Hospital. Most of the patients with THRLBCL and DLBCL presented with advanced stage disease and were classified as high‐intermediate or high‐risk groups based on their IPI score. 368 patients received R‐CHOP as first line therapy. Our data included patients who had received CNS prophylaxis. For the entire patient population, we found a 5‐year CNS relapse risk of 1.04% and 5.29% among patients with THRLBCL and DLBCL, respectively ( p < 0.001). In conclusion, THRLBCL has lowered CNS relapse risk compared to DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Oulu, Oulu, Finland.
- Faculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
- Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
- Finnish Medicines Agency (FIMEA), Helsinki, Finland.
- Department of Haematology, Oulu University Hospital, Oulu, Finland.
- Department of Pathology, Kuopio University Hospital, Kuopio, Finland.
ORCID-Profile: Atte Karhu, Milla Kuusisto, Otto Jokelainen, Minna Harmanen, Juha P Väyrynen, Joonas Kuitunen, Eetu Pellonperä, Outi Kuittinen
Förderung
- Incyte
Zitieren
APA
Karhu, A., Aronen, S., Rönkä, A., Sunela, K., Klaavuniemi, T., Aromaa-Häyhä, A., Kuusisto, M., Jokelainen, O., Böhm, J., Vuolukka, K., Arkko, U. M., Vaittinen, S., Harmanen, M., Väyrynen, J. P., Kuitunen, H., Nousiainen, S., Kuitunen, J., Kangas, J., Pellonperä, E., …, & Kuittinen, O. (2026). Low Risk of Central Nervous System Relapse Among Patients With T‐Cell/Histiocyte‐Rich Large B‐Cell Lymphoma Despite High‐Risk Disease Presentation. European Journal of Haematology, 117(2), 358-365. https://doi.org/10.1111/ejh.70190
Vancouver
Karhu A, Aronen S, Rönkä A, Sunela K, Klaavuniemi T, Aromaa-Häyhä A, et al. Low Risk of Central Nervous System Relapse Among Patients With T‐Cell/Histiocyte‐Rich Large B‐Cell Lymphoma Despite High‐Risk Disease Presentation. European Journal of Haematology. 2026;117(2):358-365. doi:10.1111/ejh.70190
BibTeX
@article{Karhu2026,
author = {Karhu, Atte and Aronen, Sara and Rönkä, Aino and Sunela, Kaisa and Klaavuniemi, Tuula and Aromaa-Häyhä, Annikki and Kuusisto, Milla and Jokelainen, Otto and Böhm, Jan and Vuolukka, Kristiina and Arkko, Ulla-Mari and Vaittinen, Samuli and Harmanen, Minna and Väyrynen, Juha P and Kuitunen, Hanne and Nousiainen, Sonja and Kuitunen, Joonas and Kangas, Juho and Pellonperä, Eetu and Kurttila, Henri and Pietilä, Miko and Tirkkonen, Jaakko and Kuittinen, Outi},
title = {Low Risk of Central Nervous System Relapse Among Patients With T‐Cell/Histiocyte‐Rich Large B‐Cell Lymphoma Despite High‐Risk Disease Presentation},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {2},
pages = {358--365},
doi = {10.1111/ejh.70190}
}
EUVIMED